Trials / Terminated
TerminatedNCT02897115
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care \[SOC\]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adalimumab | Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity. |
| OTHER | Non-steroidal Anti-inflammatory Drugs (NSAIDs) | ASAS recommended NSAID doses to treat axial spondyloarthritis. |
Timeline
- Start date
- 2016-09-12
- Primary completion
- 2017-12-21
- Completion
- 2017-12-21
- First posted
- 2016-09-13
- Last updated
- 2019-07-05
- Results posted
- 2019-07-05
Source: ClinicalTrials.gov record NCT02897115. Inclusion in this directory is not an endorsement.